Predicting Success of High-Flow Nasal Cannula in COVID-19

References

1. 1.↵
   1. Chandel A,
   2. Patolia S,
   3. Brown AW,
   4. Collins C,
   5. Sahjawani D,
   6. Khangoora V,
   7. et al

   . High-flow nasal cannula therapy in COVID-19: using the ROX index to predict success. Respir Care 2021;66(6):909-919.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Roca O,
   2. Caralt B,
   3. Messika J,
   4. Samper M,
   5. Sztrymf B,
   6. Hernández G,
   7. et al

   . An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med 2019;199(11):1368-1376.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Roca O,
   2. Messika J,
   3. Caralt B,
   4. García-de-Acilu M,
   5. Sztrymf B,
   6. Ricard J-D,
   7. et al

   . Predicting success of high-flow nasal cannula in pneumonia patients with hypoxemic respiratory failure: The utility of the ROX index. J Crit Care 2016;35:200-205.

   OpenUrlPubMed
4. 4.↵
   1. Frat JP,
   2. Thille AW,
   3. Mercat A,
   4. Girault C,
   5. Ragot S,
   6. Perbet S,
   7. et al

   . High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015;372(23):2185-2196.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. RECOVERY Trial

   . Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. Avaialble at: https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19. Accessed May 4, 2021.